Research programme: inflammation therapy - Evotec AG/Seikagaku

Drug Profile

Research programme: inflammation therapy - Evotec AG/Seikagaku

Latest Information Update: 06 Jan 2010

Price : $50

At a glance

  • Originator Evotec AG; Seikagaku Corporation
  • Class Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 26 Feb 2008 Preclinical development is ongoing
  • 13 Aug 2004 Preclinical trials in Inflammation in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top